Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis

Medicine & Life Sciences

• proinsulin-like growth factor II 100%
• Osteosclerosis 77%
• Hepatitis C 52%
• Hypoglycemia 37%
• Antibodies 28%
• Insulin-Like Growth Factor Binding Protein 2 27%
• Neoplasms 10%
• Serum 8%
• Insulin-Like Growth Factor II 8%
• Polyacrylamide Gel Electrophoresis 6%
• Osteoporosis 5%
• Osteogenesis 5%
• Amino Acids 4%
• Peptides 4%
• Therapeutics 1%

Chemical Compounds

• Insulin-Like Growth Factor II 84%
• Anabolic 36%
• Cleavage 35%
• SDS Polyacrylamide Gel Electrophoresis 26%
• Peptide 14%
• Acid 8%